Facial seborrheic dermatitis: A report on current status and therapeutic horizons

Journal of Drugs in Dermatology

Volumn 8, Issue 2, 2009, Pages 125-133

  Bikowski, Joseph ^a  

^a Bikowski Skin Care Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZELAIC ACID; BETAMETHASONE; BUTENAFINE; CICLOPIROX; CLOTRIMAZOLE; COAL TAR; DESONIDE; FLUCONAZOLE; HYDROCORTISONE; IMMUNOLOGIC FACTOR; ITRACONAZOLE; KETOCONAZOLE; LIPID; MICONAZOLE; NEUROTRANSMITTER; PIMECROLIMUS; POTASSIUM HYDROXIDE; SALICYLIC ACID; SELENIUM SULFIDE; SULFUR; TACROLIMUS; TERBINAFINE;

ACNE; ACNE VULGARIS; ALCOHOLISM; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATOPIC DERMATITIS; CANDIDIASIS; CLINICAL FEATURE; DERMATOPHYTOSIS; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EATING DISORDER; ERYTHEMA; HISTIOCYTOSIS X; HISTOLOGY; HORMONE ACTION; HUMAN; IMMUNOMODULATION; IMPETIGO; INFECTION; INFLAMMATION; LYMPHOMA; MALASSEZIA; MONOTHERAPY; NEUROLOGIC DISEASE; PHOTOTHERAPY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEA; ROSACEAFORM RASH; SEBORRHEIC DERMATITIS; SEBUM; SKIN ALLERGY; SKIN CANCER; SKIN PRURITUS; SUNLIGHT; SYSTEMIC LUPUS ERYTHEMATOSUS; TINEA; TINEA VERSICOLOR; UNSPECIFIED SIDE EFFECT; DRUG EFFECT; IMMUNOLOGY; INTRADERMAL DRUG ADMINISTRATION; MICROBIOLOGY; REVIEW; SKIN;

ACNE VULGARIS; ADMINISTRATION, CUTANEOUS; DERMATITIS, SEBORRHEIC; HUMANS; MALASSEZIA; ROSACEA; SKIN;

EID: 62449135616     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (79)

1. Peyrí J, Lleonart M; Grupo español del Estudio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis [in Spanish]. Actas Dermosifiliogr. 2007;98:476-482. (Pubitemid 47360696)
2. Bickers DR, Lim HW, Margolis D, et al. American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004. A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006;55:490-500. (Pubitemid 44209289)
3. Jesitus J. Empirical treatment is key to identifying rosacea, other dermatoses. Dermatology Times. November 1, 2007. http://www. modernmedicine.com/modernmedicine/ArticleStandard/Article/ detail/472032. Accessed May 11, 2007.
4. Del Rosso J. The prevalence of seborrheic dermatitis in patients with other commonly encountered facial dermatoses. Poster presented at the American Academy of Dermatology Summer Academy: July 28-August 1, 2004; New York, NY.
5. Gupta A. Investigating rosacea in the National Ambulatory Medical Care Survey from 1993-2002 (abstract). J Am Acad Dermatol. 2006;54(2 suppl):AB70. Abstract P576.
6. Plewig G, Jansen T. Seborrheic dermatitis. In: Wolff K, Goldsmith LA, Katz AI, et al, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill Professional; 2007:219- 225.
7. Gupta AK, Bluhm R. Seborrheic dermatitis. J Eur Acad Dermatol Venereol. 2004;18:13-26. (Pubitemid 38159356)
8. Vanbeek MJ, Strauss JS, Nygaard I. Flushing and papules in a middle- aged woman. Obstet Gynecol. 2005;105:397-401. (Pubitemid 40229461)
9. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006;74:125-130. (Pubitemid 44049740)
10. Swinyer LJ, Decroix J, Langner A, et al. Ketoconazole gel 2% in the treatment of moderate to severe seborrheic dermatitis. Cutis. 2007;79:475-482.
11. Piérard-Franchimont C, Hermanns JF, Degreef H, Piérard GE. From axioms to new insights into dandruff. Dermatology. 2000;200:93-98. (Pubitemid 30199319)
12. Crutchfield CE 3rd. Pimecrolimus: a new treatment for seborrheic dermatitis. Cutis. 2002;70:207-208.
13. Cardin C. Isolated dandruff. In: Baran R, Maibach H, eds. Textbook of Cosmetic Dermatology. Malden, MA: Blackwell Science; 1998:193-200.
14. Mathes BM, Douglass MC. Seborrheic dermatitis in patients with acquired immunodeficiency syndrome. J Am Acad Dermatol. 1985;13:947-951. (Pubitemid 16070103)
15. Cowley NC, Farr PM, Shuster S. The permissive effect of sebum in seborrhoeic dermatitis: an explanation of the rash in neurological disorders. Br J Dermatol. 1990;122:71-76. (Pubitemid 20047037)
16. Rocha N, Velho G, Horta M, et al. Cutaneous manifestations of familial amyloidotic polyneuropathy. J Eur Acad Dermatol Venereol. 2005;19:605-607. (Pubitemid 41742844)
17. Mastrolonardo M, Diaferio A, Logroscino G. Seborrheic dermatitis, increased sebum excretion, and Parkinson's disease: a survey of (im)possible links. Med Hypotheses. 2003;60:907-911. (Pubitemid 36520744)
18. Maietta G, Fornaro P, Rongioletti F, Rebora A. Patients with mood depression have a high prevalence of seborrhoeic dermatitis. Acta Derm Venereol. 1990;70:432-434. (Pubitemid 20262796)
19. Misery L, Touboul S, Vinçot C, et al. Pour le Groupe Psychodermatologie. Stress and seborrheic dermatitis. Ann Dermatol Venereol. 2007;134:833-837.
20. Berg M. Epidemiological studies of the influence of sunlight on the skin. Photodermatol. 1989;6:80-84. (Pubitemid 19152211)
21. Maietta G, Rongioletti F, Rebora A. Seborrheic dermatitis and daylight. Acta Derm Venereol. 1991;71:538-539.
22. Strumia R. Dermatologic signs in patients with eating disorders. Am J Clin Dermatol. 2005;6:165-173. (Pubitemid 40994259)
23. Rao GS. Cutaneous changes in chronic alcoholics. Indian J Dermatol Venereol Leprol. 2004;70:79-81. (Pubitemid 38978004)
24. Ro BI, Dawson TL. The role of sebaceous gland activity and scalp microfloral metabolism in the etiology of seborrheic dermatitis and dandruff. J Investig Dermatol Symp Proc. 2005;10:194-197.
25. Dawson TL Jr. Malassezia globosa and restricta: breakthrough understanding of the etiology and treatment of dandruff and seborrheic dermatitis through whole-genome analysis. J Investig Dermatol Symp Proc. 2007;12:15-19.
26. Kim BJ, Kim JY, Eun HC, et al. Androgenetic alopecia in adolescents: a report of 43 cases. J Dermatol. 2006;33:696-699. (Pubitemid 44536375)
27. Thiboutot D, Jabara S, McAllister JM, et al. Human skin is a steroidogenic tissue: steroidogenic enzymes and cofactors are expressed in epidermis, normal sebocytes, and an immortalized sebocyte cell line (SEB-1). J Invest Dermatol. 2003;120:905-914. (Pubitemid 36702897)
28. Malassez L. Note sur le champignon du pityriasis simple. Arch Physiol. 1874;1:451-459.
29. DeAngelis YM, Gemmer CM, Kaczvinsky JR, et al. Three etiologic facets of dandruff and seborrheic dermatitis: Malassezia fungi, sebaceous lipids, and individual sensitivity. J Investig Dermatol Symp Proc. 2005;10:295-297.
30. Sabouraud R. Maladies du cuir chevelu. Volume I. Les Maladies Séborrhéiques. Séborrhee, acn's, calvitie. Paris, France: Masson et Cie; 1902.
31. Tajima M, Sugita T, Nishikawa A, Tsuboi R. Molecular analysis of Malassezia microflora in seborrheic dermatitis patients: comparison with other diseases and healthy subjects. J Invest Dermatol. 2008;128:345-351.
32. Zaidi Z, Wahid Z, Cochinwala R, et al. Correlation of the density of yeast Malassezia with the clinical severity of seborrhoeic dermatitis. J Pak Med Assoc. 2002;52:504-506. (Pubitemid 36402301)
33. Heng MC, Henderson CL, Barker DC, Haberfelde G. Correlation of Pityosporum ovale density with clinical severity of seborrheic dermatitis as assessed by a simplified technique. J Am Acad Dermatol. 1990;23:82-86. (Pubitemid 20219221)
34. Ortonne JP, Lacour JP, Vitetta A, Le Fichoux Y. Comparative study of ketoconazole 2% foaming gel and betamethasone dipropionate 0.05% lotion in the treatment of seborrhoeic dermatitis in adults. Dermatology. 1992;184:275-280.
35. Bergbrant IM. Seborrhoeic dermatitis and Pityrosporum ovale: cultural, immunological and clinical studies. Acta Derm Venereol Suppl (Stockh). 1991;167:1-36.
36. Piérard-Franchimont C, Arrese JE, Pierard GE. Immunohistochemical aspects of the link between Malassezia ovalis and seborrheic dermatitis. J Eur Acad Dermatol Venereol. 1995;4:14-19.
37. Kieffer M, Bergbrant I-M, Faergemann J, et al. Immune reactions to Pityrosporum ovale in patients with atopic and seborrhoeic dermatitis. J Am Acad Dermatol. 1990;22:739-742. (Pubitemid 20154068)
38. Parry ME, Sharpe GR. Seborrhoeic dermatitis is not caused by an altered immune response to Malassezia yeast. Br J Dermatol. 1998;139:254-263. (Pubitemid 28389398)
39. Midgley G, Hay RJ. Serological responses to Pityrosporum (Malassezia) in seborrhoeic dermatitis demonstrated by ELISA and Western blotting. Bull Soc Fr Mycol Med. 1988;17:267-276.
40. Midgley G. The lipophilic yeasts: state of the art and prospects. Med Mycol. 2000;38(suppl 1):9-16. (Pubitemid 32094050)
41. Ashbee HR. Update on the genus Malassezia. Med Mycol. 2007;45:287-303. (Pubitemid 46839800)
42. Faergemann J, Bergbrant IM, Dohsé M, et al. Seborrhoeic dermatitis and Pityrosporum (Malassezia) folliculitis: characterization of inflammatory cells and mediators in the skin by immunohistochemistry. Br J Dermatol. 2001;144:549-556. (Pubitemid 32232010)
43. Nnoruka EN, Chukwuka JC, Anisuiba B. Correlation of mucocutaneous manifestations of HIV/AIDS infection with CD4 counts and disease progression. Int J Dermatol. 2007;46(suppl 2):14-18. (Pubitemid 350066590)
44. Goh BK, Chan RK, Sen P, et al. Spectrum of skin disorders in human immunodeficiency virus-infected patients in Singapore and the relationship to CD4 lymphocyte counts. Int J Dermatol. 2007;46:695-699. (Pubitemid 47046185)
45. Soeprono FF, Schinella RA, Cockerell CJ, Comite SL. Seborrheiclike dermatitis of acquired immunodeficiency syndrome. A clinicopathologic study. J Am Acad Dermatol. 1986;14(2 Pt 1):242-248. (Pubitemid 16068073)
46. What is rosacea? International Rosacea Foundation Web site. http://www.internationalrosaceafoundation.org/. Accessed May 19, 2008.
47. Warshaw EM, Wohlhuter RJ, Liu A, et al. Results of a randomized, double-blind, vehicle-controlled efficacy trial of pimecrolimus cream 1% for the treatment of moderate to severe facial seborrheic dermatitis [published online ahead of print December 22, 2006]. J Am Acad Dermatol. 2007;57:257-264. (Pubitemid 47048856)
48. Bikowski J, Del Rosso J. Photographic results of biorestorative skin cream in the treatments of rosacea and seborrheic dermatitis [poster]. J Am Acad Dermatol. 2006;54(2 suppl):AB72. Abstract P586.
49. Draelos Z. An efficacy assessment of a novel skin cleansing device in seborrheic dermatitis [abstract]. J Am Acad Dermatol. 2007;56(2 suppl):AB51. Abstract P544.
50. Mills K, Suszcynsky-Meister E, Kincaid E, Copas E. Ceramide insufficiency in dandruff/seborrheic dermatitis stratum corneum is reversed by potentiated micronized platelet pyrithione zinc shampoo treatment [poster]. J Am Acad Dermatol. 2008;58(2 suppl):AB41. Abstract 436.
51. Faergemann J, Johansson B, Hornby S, Wahlstrand B. Clinical value of a clean rinsing bar in reducing skin flora [abstract]. J Am Acad Dermatol. 2008;58(2 suppl):AB69. Abstract P928.
52. Lübbe J, Saurat JH. A monograph on topical tacrolimus (Protopic®) . Ann Dermatol Venereol. 2003;130:290-302.
53. Antille C, Saurat JH, Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol. 2004;140:457-460. (Pubitemid 38469249)
54. Bunting S. Tacrolimus 0.1% ointment for facial seborrheic dermatitis: A randomized, double-blind, placebo-controlled trial [abstract]. J Am Acad Dermatol. 2006;54(3 suppl):AB208. Abstract 2840.
55. Firooz A, Solhpour A, Gorouhi F, et al. Pimecrolimus cream, 1%, vs hydrocortisone acetate cream, 1%, in the treatment of facial seborrheic dermatitis: a randomized, investigator-blind, clinical trial. Arch Dermatol. 2006;142:1066-1067. (Pubitemid 44268490)
56. Gorman CR, White SW. Rosaceiform dermatitis as a complication of treatment of facial seborrheic dermatitis with 1% pimecrolimus cream. Arch Dermatol. 2005;141:1168. (Pubitemid 41373973)
57. Yarosh DB, Pena AV, Nay SL, et al. Calcineurin inhibitors decrease DNA repair and apoptosis in human keratinocytes following ultraviolet B irradiation. J Invest Dermatol. 2005;125:1020-1025.
58. Elidil [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; August 2007.
59. Prograf [package insert]. Deerfield, IL: Astellas Pharma US, Inc.; April 2006.
60. US Food and Drug Administration. FDA public health advisory: Elidel (pimecrolimus) cream and Protopic (tacrolimus) ointment. FDA Center for Drug Evaluation and Research Web site. http:// www.fda.gov/CDER/DRUG/advisory/elidel- protopic.htm. Published March 10, 2005. Accessed May 20, 2008.
61. Elewski BE, Abramovits W, Kempers S, et al. A novel foam formulation of ketoconazole 2% for the treatment of seborrheic dermatitis on multiple body regions. J Drugs Dermatol. 2007;6:1001-1008.
62. Van Gerven F, Odds FC. The anti-Malassezia furfur activity in vitro and in experimental dermatitis of six imidazole antifungal agents: bifonazole, clotrimazole, flutrimazole, ketoconazole, miconazole and sertaconazole. Mycoses. 1995;38:389-393.
63. Faergemann J. Seborrhoeic dermatitis and Pityrosporum orbiculare: treatment of seborrhoeic dermatitis of the scalp with miconazole- hydrocortisone (Daktacort), miconazole and hydrocortisone. Br J Dermatol. 1986;114:695-700. (Pubitemid 16079770)
64. Sheth RA.A comparison of miconazole nitrate and selenium disulfide as anti-dandruff agents. Int J Dermatol. 1983;22(2):123-125 (Pubitemid 13165414)
65. Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004;5:417-422. (Pubitemid 40175259)
66. Parish L, Parish L, Routh H. Selenium sulfide in the 21st century [poster]. J Am Acad Dermatol. 2008;58(2 suppl):AB72. Abstract P939.
67. Zisova LG. Fluconazole and its place in the treatment of seborrheic dermatitis-new therapeutic possibilities. Folia Med (Plovdiv). 2006;48:39-45.
68. Kose O, Erbil H, Gur AR. Oral itraconazole for the treatment of seborrhoeic dermatitis: an open, noncomparative trial. J Eur Acad Dermatol Venereol. 2005;19:172-175. (Pubitemid 40450419)
69. Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new treatment for papulopustular rosacea: results from two vehicle-controlled, randomized phase III studies. J Am Acad Dermatol. 2003;48:836-845. (Pubitemid 36706214)
70. Elewski BE, Fleischer AB Jr, Pariser DM. A comparison of 15% azelaic acid gel and 0.75% metronidazole gel in the topical treatment of papulopustular rosacea: results of a randomized trial. Arch Dermatol. 2003;139:1444-1450. (Pubitemid 37433134)
71. Stinco G, Bragadin G, Trotter D, et al. Relationship between sebostatic activity, tolerability and efficacy of three topical drugs to treat mild to moderate acne. J Eur Acad Dermatol Venereol. 2007;21:320-325.
72. Passi S, Picardo M, De Luca C, et al. Scavenging activity of azelaic acid on hydroxyl radicals "In Vitro." Free Radic Res Commun. 1991;11:329-338.
73. Passi S, Picardo M, Zompetta C, et al. The oxyradical-scavenging activity of azelaic acid in biological systems. Free Radic Res Commun. 1991;15:17-28.
74. Akamatsu H, Komura J, Asada Y, et al. Inhibitory effect of azelaic acid on neutrophil functions: a possible cause for its efficacy in treating pathogenetically unrelated diseases. Arch Dermatol Res. 1991;283:162-166.
75. Del Rosso JQ, Baum EW, Draelos ZD, et al. Azelaic acid gel 15%: clinical versatility in the treatment of rosacea. Cutis. 2006;78(5 suppl):6-19. (Pubitemid 44952086)
76. Passi S, Picardo M, De Luca C, Nazzaro-Porro M. Mechanism of azelaic acid action in acne [in Italian]. G Ital Dermatol Venereol. 1989;124:455-463. (Pubitemid 20153963)
77. Brasch J, Christophers E. Azelaic acid has antimycotic properties in vitro. Dermatology. 1993;186:55-58. (Pubitemid 23032321)
78. Data on file, Intendis, GmbH.
79. Reich K, Friedrich M, Graupe K. A double-blind, vehicle-controlled study of the efficacy and safety of azelaic acid (AzA) 15% gel in mild to moderate seborrheic dermatitis. Poster presented at the 21st World Congress of Dermatology; October 1-10, 2007; Buenos Aires, Argentina. Abstract 6686.